For all aforementioned reasons, and in view of the complexity and multifactorial character of hypertension, the failure of RDN to normalize or substantially reduce blood pressure in all patients with apparently TRH was a reasonable working hypothesis for us, even before the Medtronic announcement that Symplicity HTN-3 had failed to meet its primary endpoint (http://www.tctmd.com/show.aspx?id=123265). Here, TRH is linked to hypertensive disorder.